918867-03-5

Basic information

• Product Name: 2-hexacosanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-3,4-O-isopropylidene-D-ribo-1,3,4-tricosanetriol
• Synonyms: 2-hexacosanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-3,4-O-isopropylidene-D-ribo-1,3,4-tricosanetriol
• CAS NO: 918867-03-5
• Molecular Weight: 1329.04
• Mol File: 918867-03-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-hexacosanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-3,4-O-isopropylidene-D-ribo-1,3,4-tricosanetriol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hexacosanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-3,4-O-isopropylidene-D-ribo-1,3,4-tricosanetriol(918867-03-5)
• EPA Substance Registry System: 2-hexacosanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-3,4-O-isopropylidene-D-ribo-1,3,4-tricosanetriol(918867-03-5)

Safety Data

• Hazardous Substances Data: 918867-03-5(Hazardous Substances Data)

Upstream product

• 918867-02-4 2-amino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-3,4-O-isopropylidene-D-ribo-1,3,4-tricosanetriol 
• 506-46-7 1-hexacosanoic acid 

Downstream Products

• 918867-04-6 2-hexacosanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-D-ribo-1,3,4-tricosanetriol 

Relevant articles and documents

GLYCOLIPID DERIVATIVE AND THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT

A glycolipid derivative represented by the formula (I): (I) wherein R1 represents an aldopyranaose residue, R2 represents a hydrogen atom or a hydroxyl group, A represents -CH2-,-CH(OH)-CH2- or -CH=CHCH2-, Z represents -O- or -CH2-, and y represents an integer of 26 to 35 when Z represents -O- and x represents an integer of 4 to 16, y represents an integer of 0 to 35 when Z represents -O- and x represents an integer of 17 to 25, y represents an integer of 26 to 35 when Z represents -CH2- and x represents an integer of 4 to 15 and y represents an integer of 0 to 35 when Z represents -CH2- and x represents an integer of 16 to 25; and a therapeutic agent for an autoimmune disease (e.g., autoimmune arthritis), an allergic disease (e.g., bronchial asthma) or a disease of which an NKT cell or the stimulation of an NKT cell is known to be involved in the aggravation of the condition comprising the glycolipid derivative.